Bruker: Back to The Future

It's been a while but Bruker is finally ready to compound again

Friends of NFTBC

Yesterday was a busy day with four of our stocks of interest reporting. I intend to visit them all, but not necessarily in standalone posts - so keep an eye out in The NFTBC Digest. There’s also a new long-form post in the works for the coming days, so keep an eye out for that one too.

I began my BRKR deep dive last year with this 2010 quote from Nobel Prize winner Richard Ernst:

And what is the moral of the success story of the Bruker Corporation? Bruker has been active in a unique manner in a high-tech leading field over an incredibly long period of 50 years. Few other companies can match Bruker. Whatever Bruker has achieved has demanded novel technologies that in each case would have been impossible a few years earlier. For academia, such companies are ideal partners: they are highly ambitious, stimulating, and grateful for creative contributions.

This form of exchange can indeed be highly motivating for inventive entrepreneurs and for innovative researchers with endurance. Ultimately, it is courageous and creative efforts that are decisive. The example of Varian also shows that initial success can lead to complacency and the underestimation of motivated competitors. One further lesson that can be drawn concerns company leadership. One should guard oneself from companies that are managed by technically illiterate lawyers and MBAs. Technical expertise coupled to close contact with the market remains essential for avoiding flawed decisions. Bruker has in the past evaded such perils through wise personnel policies and long-term continuity. The company has produced beneficial innovations and added value for 50 years. Also investors might derive lessons: it is still the rock-solid technical expertise of a CEO together with their market awareness that offer the best guarantees against false decisions. With innovative companies, like the Bruker Corporation, the frequently forecast demise of Europe is not imminent. Even if the Bruker Corporation is of late governed by American law, the spirit of this remarkable company is still firmly European.

As I said at the time, this continues to more or less sum up the BRKR thesis, a decade and a half after it was written. Ernst was talking about Nuclear Magnetic Resonance, where BRKR now has 100% market share in high field systems - when you can do things that others cannot that’s usually a valuable proposition. A similar dynamic reaches out into numerous other fields with compelling longer-term tailwinds, whether that’s in the life science domain, semiconductor metrology, nuclear fusion, the list goes on - and it’s an eclectic list that generally goes quite under-appreciated. Over the course of the last 12 months, since I posted the deep dive, the company has continued to push in this direction by launching breakthrough instruments with the potential to open up new markets - these include timsOmni (functional proteomics), timsMetabo (4D metabolomics), PaintScape (3D genomics) and others. While it’s too early to know what the eventual financial impact of incremental innovations will be, the contribution to the order book is already showing up and the impact on intrinsic value likely to be material over time. In the context of last year’s dilution saga, things ain’t so bad then. Moreover, we can now be quite confident that the next major multi-year earnings growth story is finally underway, starting Q2 2026: back to the future.

In the remainder of this post we’ll take a look at some of takeaways from yesterday’s earnings materials. One last thing: for a limited period I have taken the paywall off the original deep dive for anyone who’d like to see it. I just ask that you kindly hit the like and share buttons.

[NFTBC does not give advice - please do your own research. I currently own Bruker shares].